BRIDGEWATER, N.J., Jan. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 7:30 a.m. ET.
The presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of each live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States and the European Union to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit www.insmed.com.
Contact:
Investors:
Argot PartnersLaura Perry or Heather Savelle(212) 600-1902insmed@argotpartners.com
Media:
Mandy FaheySenior Director, Corporate CommunicationsInsmed(732) 718-3621amanda.fahey@insmed.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301197064.html
SOURCE Insmed Incorporated